CagriSema Falls Short vs Zepbound in Head-to-Head Trial
Novo’s new obesity shot CagriSema lost a head-to-head battle with Lilly’s tirzepatide. 23% weight loss is strong but not enough to win this round.
/ 84 items
#NVO↓
Novo Nordisk Sues Hims & Hers Over Weight-Loss Drug Knockoffs
Danish pharma giant Novo Nordisk files patent lawsuit against telehealth company Hims & Hers for selling unauthorized versions of Wegovy and Ozempic weight-loss medications.
Hims Pulls Copycat Wegovy Weight-Loss Pill After Federal Pressure
Hims & Hers Health stops selling its cheaper Wegovy copycat pill just two days after launch following FDA crackdown and Justice Department investigation into compounded weight-loss drugs.
FDA Cracks Down on Compounded GLP-1 Weight Loss Drugs
FDA plans to restrict non-approved compounded GLP-1 drugs sold by Hims & Hers and compounding pharmacies, citing safety concerns and misleading marketing practices.
Hims vs. Novo Nordisk: Why the Pharma Giant Might Avoid a Legal Fight
Hims is selling a $49 copycat of Novo Nordisk's $149 weight-loss pill, but legal experts say Novo may avoid court battles due to risks of setting dangerous precedents.
FDA Commissioner Warns Against "Illegal Copycat" Weight-Loss Drugs
FDA takes aim at compounded weight-loss drugs like Hims' $49 Wegovy alternative, raising safety concerns over unapproved copycat medications flooding the market.